| Q34274434 | 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension |
| Q56970799 | 2007 ESH‐ESC Guidelines for the management of arterial hypertension |
| Q38071039 | 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American |
| Q34565643 | 2014 hypertension recommendations from the eighth joint national committee panel members raise concerns for elderly black and female populations. |
| Q64080237 | 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension |
| Q47430437 | 24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension |
| Q37656205 | 7th Brazilian Guideline of Arterial Hypertension: Chapter 7 - Pharmacological Treatment |
| Q27231406 | A Randomized Trial of Intensive versus Standard Blood-Pressure Control |
| Q83131324 | A cost-utility analysis of losartan versus atenolol in the treatment of hypertension with left ventricular hypertrophy |
| Q34328239 | A critique of hypertension treatment trials and of their evaluation |
| Q28196568 | A cure for cardiovascular disease? Combination treatment has enormous potential, especially in developing countries |
| Q28219234 | A new paradigm of cardiovascular risk factor modification |
| Q28472432 | A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials |
| Q73283629 | A one-quarter reduction in the salt content of bread can be made without detection |
| Q38697113 | A profile of adverse effects of antihypertensive medicines in a tertiary care clinic in Nigeria |
| Q34738073 | A retrospective electronic chart review of blood pressure changes in elderly patients treated with amlodipine or an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker |
| Q36490906 | A study on prescribing patterns of antihypertensives in geriatric patients |
| Q34265526 | A web-based patient activation intervention to improve hypertension care: Study design and baseline characteristics in the web hypertension study |
| Q33636677 | ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. |
| Q33576830 | ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses |
| Q35106205 | ALLHAT: definitive answers or continuing uncertainty? |
| Q58554987 | Accelerated DNA methylation age and the use of antihypertensive medication among older adults |
| Q36684801 | Achieving blood pressure goals: why aren't we? |
| Q44491535 | Achieving goal blood pressure in patients with type 2 diabetes: conventional versus fixed-dose combination approaches |
| Q77160540 | Active-control equivalence trials and antihypertensive agents |
| Q59586829 | Acute effects of calcium supplements on blood pressure: randomised, crossover trial in postmenopausal women |
| Q38574447 | Acute myocardial infarction and influenza: a meta-analysis of case-control studies |
| Q33696605 | Adherence level of antihypertensive agents in coronary artery disease |
| Q36475160 | Adherence to antihypertensive medications: is prescribing the right pill enough? |
| Q44701637 | Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy |
| Q34001855 | Adherence to beta-blocker therapy under drug cost-sharing in patients with and without acute myocardial infarction |
| Q34247990 | Agency social workers could monitor hypertension in the community |
| Q61249004 | Aging diseases - do they prevent preventive health care from saving costs? |
| Q81780631 | Alcohol consumption and hypertension |
| Q43208657 | Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial |
| Q35876368 | Aliskiren in hypertension: evidence for its potential therapeutic value |
| Q36903748 | Aliskiren: a review of its use in the management of hypertension |
| Q39148910 | Ambiguities in the Guidelines for the Management of Arterial Hypertension: Indian Perspective with a Call for Global Harmonization. |
| Q92510342 | Ambulatory Blood Pressure Reduction With SGLT-2 Inhibitors: Dose-Response Meta-analysis and Comparative Evaluation With Low-Dose Hydrochlorothiazide |
| Q34145117 | An evaluation of a clinical pharmacy-directed intervention on blood pressure control |
| Q92179609 | Analysis of antihypertensive treatment using real-world Japanese data-the retrospective study of antihypertensives for lowering blood pressure (REAL) study |
| Q38696001 | Aneurysms of the ascending aorta and aortic arch |
| Q34628700 | Angiotensin II Type 1 receptor antagonists in chronic heart failure |
| Q47361918 | Angiotensin II blockade: a therapeutic strategy with wide applications. |
| Q35815199 | Angiotensin II status and sympathetic activation among hypertensive patients in Uganda: a cross-sectional study |
| Q36214898 | Angiotensin II-receptor antagonist in the treatment of hypertension |
| Q35579603 | Angiotensin converting enzyme inhibition and hospitalisation rates for heart failure in the Netherlands, 1980 to 1999: the end of an epidemic? |
| Q36242608 | Angiotensin receptor blockers: therapeutic targets and cardiovascular protection |
| Q36060436 | Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? |
| Q35258897 | Angiotensin-converting enzyme inhibition and novel cardiovascular risk biomarkers: results from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study |
| Q35875450 | Angiotensin-converting enzyme inhibitors and stroke risk: benefit beyond blood pressure reduction? |
| Q57781886 | Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or β-blockers |
| Q36039063 | Antecedents to effective treatment of hypertension in Hispanic populations |
| Q55487906 | Antihypertensive Medicines Prescriptions before and after the Nigeria Hypertension Society Guidelines and Prescriber's Awareness of the Guideline. |
| Q40220460 | Antihypertensive adherence and drug class among Asian Pacific Americans |
| Q39221717 | Antihypertensive adherence and outcomes among community-dwelling Medicare beneficiaries: the Atherosclerosis Risk in Communities Study |
| Q39793210 | Antihypertensive drugs and inflammation in acute ischemic stroke as a predictor factor of future cardiovascular mortality |
| Q34482372 | Antihypertensive effect of manidipine |
| Q80397837 | Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension |
| Q79427749 | Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals |
| Q33561456 | Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects |
| Q36684797 | Antihypertensive prescribing practices: impact of the antihypertensive and lipid-lowering treatment to prevent heart attack trial |
| Q35036478 | Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor? |
| Q78871466 | Are cholesterol-lowering medications and antihypertensive agents preventing stroke in ways other than by controlling the risk factor? |
| Q37224469 | Are hypertensive elderly patients treated differently? |
| Q35115565 | Are we satisfied with the follow-up of hypertensive and chronic kidney disease patients in outpatient clinics? |
| Q36766087 | Arterial hypertension in diabetes mellitus: from theory to clinical practice. |
| Q36009879 | Arterial stiffness and stroke in hypertension: therapeutic implications for stroke prevention |
| Q36596072 | Association between insufficient medication of antihypertensives and the severity of acute ischemic stroke. |
| Q37605751 | Association of obstructive sleep apnea plus hypertension and prevalent cardiovascular diseases: A cross-sectional study |
| Q58701203 | Asymptomatic Carotid Stenosis: Intervention or Best Medical Therapy? |
| Q35143216 | Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target |
| Q35984204 | Balancing Model Performance and Simplicity to Predict Postoperative Primary Care Blood Pressure Elevation |
| Q36729160 | Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events |
| Q24799267 | Benefits and side effects of blood pressure lowering treatment: what was wrong with doxazosin in the ALLHAT? |
| Q35545484 | Benefits of blood pressure reduction in diabetic patients |
| Q44280391 | Best bang for the buck? |
| Q35062803 | Better blood pressure control: how to combine drugs |
| Q38005041 | Beyond blood pressure: evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers |
| Q38605174 | Biochemical Screening for Nonadherence Is Associated With Blood Pressure Reduction and Improvement in Adherence. |
| Q38081905 | Biological variation of cardiovascular risk factors in patients with diabetes. |
| Q38647811 | Blood Pressure Targets and Clinical Outcomes in Patients with Acute Myocardial Infarction |
| Q34163961 | Blood pressure and human genetic variation in the general population |
| Q36671113 | Blood pressure and site-specific cancer mortality: evidence from the original Whitehall study |
| Q43907270 | Blood pressure and stroke; the PROGRESS trial |
| Q35722933 | Blood pressure control and nephroprotection in diabetes |
| Q35087527 | Blood pressure control--effects on diabetic nephropathy progression: how low does blood pressure have to be? |
| Q34507164 | Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis |
| Q49589225 | Blood pressure profile is associated with microalbuminuria and retinopathy in hypertensive nondiabetic patients |
| Q80220592 | Blood pressure, antihypertensive treatment and factors associated with good blood pressure control in hypertensive diabetics: the Tarmidas study |
| Q52646677 | Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. |
| Q43410417 | Blood-pressure-lowering treatment |
| Q44352125 | Blood-pressure-lowering treatment |
| Q73612710 | Blood-pressure-lowering treatment |
| Q74253925 | Blood-pressure-lowering treatment |
| Q93949440 | Blood-pressure-lowering treatment |
| Q93949444 | Blood-pressure-lowering treatment |
| Q28167733 | British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary |
| Q37416133 | CYP3A5 and ABCB1 genes and hypertension |
| Q35207589 | Calcium antagonists in the treatment of hypertension in patients with ischaemic heart disease |
| Q34849534 | Calcium channel blockade in combination with angiotensin-converting enzyme inhibition or angiotensin II (AT(1)-receptor) antagonism in hypertensive diabetics and patients with renal disease and hypertension |
| Q51245729 | Caloric Restriction and Its Effect on Blood Pressure, Heart Rate Variability and Arterial Stiffness and Dilatation: A Review of the Evidence. |
| Q37284841 | Cancer Stem Cells in Moderately Differentiated Buccal Mucosal Squamous Cell Carcinoma Express Components of the Renin-Angiotensin System |
| Q41320360 | Cancer stem cells in moderately differentiated oral tongue squamous cell carcinoma express components of the renin-angiotensin system |
| Q34636660 | Candesartan cilexetil: an update of its use in essential hypertension |
| Q35752993 | Cardio classics revisited: focus on the role of amlodipine |
| Q38707980 | Cardiovascular Health and Incident Hypertension in Blacks: JHS (The Jackson Heart Study). |
| Q56504913 | Cardiovascular Risk Factors. Insights From Framingham Heart Study |
| Q46028082 | Cardiovascular disease and modifiable cardiometabolic risk factors. |
| Q26769978 | Cardiovascular drugs in the treatment of infantile hemangioma |
| Q34522261 | Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol |
| Q35748201 | Cathepsin-L, a key molecule in the pathogenesis of drug-induced and I-cell disease-mediated gingival overgrowth: a study with cathepsin-L-deficient mice |
| Q44934166 | Change in stroke incidence, mortality, case-fatality, severity, and risk factors in Oxfordshire, UK from 1981 to 2004 (Oxford Vascular Study). |
| Q39023235 | Changes in Non-Diabetic Comorbid Disease Status Following Laparoscopic Vertical Sleeve Gastrectomy (LVSG) Versus Laparoscopic Roux-En-Y Gastric Bypass (LRYGB) Procedures: a Systematic Review of Randomized Controlled Trials |
| Q34677697 | Changes in blood pressure among students attending Glasgow University between 1948 and 1968: analyses of cross sectional surveys |
| Q78374876 | Changing patterns of initial drug therapy for the treatment of hypertension in a Medicaid population, 1997-2000 |
| Q61911444 | Chapter 20 Epidemiological implications of primary and secondary stroke prevention |
| Q37098630 | Characteristics of patients prescribed angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the combination at an urban medical center |
| Q44621227 | Choice of treatment: outcomes and treatment goals |
| Q57067775 | Choices for long-term hypertensive control in patients after first-ever hemorrhagic stroke: a nationwide cohort study |
| Q35205363 | Clinical and economic considerations of antiobesity treatment: a review of orlistat |
| Q38074768 | Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations |
| Q44046667 | Clinical pharmacology-physiology conference. A chrono-therapeutic approach to the treatment of hypertension |
| Q35079837 | Clinical trial experience around the globe: focus on calcium-channel blockers. |
| Q81780627 | Clinical trials report. The CAMELOT Study |
| Q34513022 | Clustering of risk factors: a simple method of detecting cardiovascular disease in youth |
| Q46823637 | Combination polypharmacy for cardiovascular disease prevention in men: a decision analysis and cost-effectiveness model |
| Q43201416 | Combination therapy with angiotensin-converting enzyme inhibitors and indapamide impairs glucose tolerance in Chinese hypertensive patients |
| Q34849510 | Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension |
| Q47447764 | Comorbidity Status and Annual Total Medical Expenditures in U.S. Hypertensive Adults |
| Q33997802 | Comparative effectiveness of 2 β-blockers in hypertensive patients |
| Q37189020 | Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension |
| Q36829007 | Compliance and fixed-dose combination therapy. |
| Q34990467 | Compliance and persistence with newer antihypertensive agents |
| Q36975953 | Construction of a three-dimensional model of cardiovascular disease and deployment of a new method of fostering patient adherence to instruction |
| Q36852813 | Continuing versus Stopping Prestroke Antihypertensive Therapy in Acute Intracerebral Hemorrhage: A Subgroup Analysis of the Efficacy of Nitric Oxide in Stroke Trial |
| Q28166294 | Coronary heart disease prevention: insights from modelling incremental cost effectiveness |
| Q34640666 | Cost effective interventions for the prevention of cardiovascular disease in low and middle income countries: a systematic review |
| Q49889501 | Cost-effectiveness Analyses of Antihypertensive Medicines: A Systematic Review |
| Q46112487 | Cost-effectiveness analysis of interventions to prevent cardiovascular disease in Vietnam |
| Q34247622 | Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: a pharmacoeconomic comparison of antihypertensive efficacy of beta blockers |
| Q30499940 | Cost-effectiveness of a hypertension management programme in an elderly population: a Markov model. |
| Q43411786 | Cost-effectiveness of irbesartan/hydrochlorothiazide in patients with hypertension: an economic evaluation for Sweden |
| Q28219296 | Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country--the case of Tanzania |
| Q33355842 | Costs of hospital care for hypertension in an insured population without an outpatient medicines benefit: an observational study in the Philippines |
| Q44564244 | Creating a combination antihypertensive regimen: what does the research show? |
| Q37616369 | Cultural Dance Program Improves Hypertension Management for Native Hawaiians and Pacific Islanders: a Pilot Randomized Trial |
| Q38771123 | Current Trends of Hypertension Treatment in the United States. |
| Q43116133 | Current status of antihypertensive drug treatment in primary care practice at launch of the new renin inhibitor aliskiren (RASANT) |
| Q35166368 | Current treatment of patients with hypertension: therapeutic implications of INSIGHT. |
| Q34738480 | Cyclo-oxygenase-2-specific inhibitors and cardiovascular morbidity |
| Q35143220 | Debate: angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers--a gap in evidence-based medicine |
| Q24792999 | Debate: does it matter how you lower blood pressure? |
| Q38610828 | Decision-making using absolute cardiovascular risk reduction and incremental cost-effectiveness ratios: a case study |
| Q53119815 | Defining the role of pharmacology in the emerging world of translational research. |
| Q35992372 | Design and rationale for Home Blood Pressure Telemonitoring and Case Management to Control Hypertension (HyperLink): a cluster randomized trial. |
| Q36530194 | Desirable therapeutic characteristics of an optimal antihypertensive agent |
| Q35183990 | Diabetes and vascular disease: a new international trial |
| Q33769796 | Dietary sodium and potassium intake is not associated with elevated blood pressure in US adults with no prior history of hypertension |
| Q45974501 | Difference of antihypertensive prescribing between office- and hospital-based clinics in Taiwan. |
| Q35166628 | Differential associations between actual and expected GP practice prescribing rates for statins, ACE inhibitors, and beta-blockers: a cross-sectional study in England |
| Q37101452 | Dihydropyridine calcium channel blockers and cardiovascular outcomes in elderly patients: a population-based study |
| Q37215566 | Direct renin inhibition: an analysis of possible benefits |
| Q39694133 | Discontinuation of angiotensin-converting enzyme inhibitors: a cohort study |
| Q24806951 | Diuretics: again the first step in the treatment of most patients with hypertension |
| Q35696465 | Diuretics: drugs of choice for the initial management of patients with hypertension |
| Q57781897 | Diuretic–gene interaction and the risk of myocardial infarction and stroke |
| Q80130803 | Doctors and the public concord in their acceptance of antihypertensive drug treatment |
| Q37684944 | Does Pomegranate intake attenuate cardiovascular risk factors in hemodialysis patients? |
| Q37000891 | Does it matter how you lower blood pressure in patients with uncomplicated hypertension? Weighing the evidence |
| Q37099019 | Doxazosin in the current treatment of hypertension |
| Q43649679 | Drug therapy for management of obesity |
| Q78773648 | Drug treatment of hypertension |
| Q34981356 | Drugs targeting the renin-angiotensin-aldosterone system |
| Q48845833 | EBM: a narrow and obsessive methodology that fails to meet the knowledge needs of a complex adaptive clinical world: a commentary on Djulbegovic, B., Guyatt, G. H. & Ashcroft, R. E. (2009) Cancer Control, 16, 158-168. |
| Q36409170 | Economic analysis of Heart and Stroke Foundation of Ontario's Hypertension Management Initiative |
| Q42844891 | Effect of Early Diabetes on the Response to Norepinephrine and Dopamine in Pithed Wistar Kyoto and Spontaneously Hypertensive Rats |
| Q38984580 | Effect of Nigella sativa supplementation over a one-year period on lipid levels, blood pressure and heart rate in type-2 diabetic patients receiving oral hypoglycemic agents: nonrandomized clinical trial |
| Q36938839 | Effect of amlodipine on cardiovascular events in hypertensive haemodialysis patients |
| Q37030912 | Effect of cold spells and their modifiers on cardiovascular disease events: Evidence from two prospective studies |
| Q35876331 | Effect of immunosuppressive agents on long-term survival of renal transplant recipients: focus on the cardiovascular risk |
| Q34346106 | Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial |
| Q33413288 | Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials |
| Q36572955 | Effective management of hypertension with dihydropyridine calcium channel blocker-based combination therapy in patients at high cardiovascular risk |
| Q44350190 | Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk |
| Q36119110 | Effectiveness of multidisciplinary intervention on blood pressure control in primary health care: a randomized clinical trial |
| Q57065870 | Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT |
| Q46877368 | Effects of a benidipine-based combination therapy on the risk of stroke according to stroke subtype: the COPE trial |
| Q37204638 | Effects of a web-based patient activation intervention to overcome clinical inertia on blood pressure control: cluster randomized controlled trial |
| Q37728140 | Effects of allisartan, a new AT(1) receptor blocker, on blood pressure and end-organ damage in hypertensive animals |
| Q41734583 | Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials |
| Q36761442 | Effects of blood pressure reduction on cardiovascular risk estimates in hypertensive postmenopausal women |
| Q94339392 | Effects of different blood-pressure-lowering regimens on major cardiac events |
| Q33870283 | Effects of the dietary approaches to stop hypertension diet alone and in combination with exercise and caloric restriction on insulin sensitivity and lipids |
| Q44313582 | Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease |
| Q51752291 | Efficacy and Safety of Valsartan 160mg/Hydrochlorothiazide 25mg Combination in Patients with Hypertension not Adequately Controlled by Valsartan 160mg/Hydrochlorothiazide 12.5mg. |
| Q40009748 | Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers in Coronary Artery Disease without Heart Failure in the Modern Statin Era: a Meta-Analysis of Randomized-Controlled Trials. |
| Q41613442 | Efficacy of Chinese herbal medicine for stroke modifiable risk factors: a systematic review. |
| Q34701662 | Efficacy of a brief multifactorial adherence-based intervention in reducing blood pressure: a randomized clinical trial. |
| Q33702851 | Efficacy of a brief multifactorial adherence-based intervention on reducing the blood pressure of patients with poor adherence: protocol for a randomized clinical trial |
| Q37539540 | Efficacy of a text messaging (SMS) based intervention for adults with hypertension: protocol for the StAR (SMS Text-message Adherence suppoRt trial) randomised controlled trial |
| Q37772161 | Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan |
| Q35129507 | Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial |
| Q35602652 | Emerging drugs in the management of hypertension |
| Q37449319 | Enhanced blood pressure-lowering effect of olmesartan in hypertensive patients with chronic kidney disease-associated sympathetic hyperactivity: HONEST study. |
| Q38360767 | Environmental origins of hypertension: phylogeny, ontogeny and epigenetics |
| Q38110711 | Epidemiology, prognosis, and treatment of resistant hypertension |
| Q37632388 | Eprosartan: a review of its use in hypertension |
| Q57085592 | Essential hypertension |
| Q37064847 | Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy |
| Q38999152 | Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Car |
| Q48939835 | Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart Association and American College of Car |
| Q34134078 | Evaluation of thiazide diuretic use as preferred therapy in uncomplicated essential hypertension patients |
| Q84978295 | Evidence-based practice guideline for the treatment of CKD |
| Q38169038 | Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association |
| Q89514359 | Financial incentives for hypertension control: rationale and study design |
| Q36065115 | Finding Alternatives to the Dogma of Power Based Sample Size Calculation: Is a Fixed Sample Size Prospective Meta-Experiment a Potential Alternative? |
| Q56336831 | First-line drugs for hypertension |
| Q30808567 | Frequency of cardiovascular events in patients treated with anti hypertensive agents: A cohort study based on claims data generated by primary care practice |
| Q44366068 | Frequency of stroke types at an emergency hospital in Natal, Brazil. |
| Q34971717 | Future management of carotid stenosis: role of urgent carotid interventions in the acutely symptomatic carotid patient and best medical therapy for asymptomatic carotid disease |
| Q88345982 | Genetic Variants Influencing Plasma Renin Activity in Hypertensive Patients From the PEAR Study (Pharmacogenomic Evaluation of Antihypertensive Responses) |
| Q46410618 | Geospatial patterns of hospitalization rates for stroke with comorbid hypertension in relation to environmental sources of persistent organic pollutants: results from a 12-year population-based study |
| Q39252137 | Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. |
| Q34775810 | Global burden of blood-pressure-related disease, 2001. |
| Q34299778 | Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. |
| Q22306361 | Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association |
| Q41032176 | HYT-hypertension in Turkey: a cross-sectional survey on blood pressure control with calcium channel blockers alone or combined with other antihypertensive drugs. |
| Q35170117 | Has the role of calcium channel blockers in treating hypertension finally been defined? |
| Q36928506 | Heart failure in South Asia |
| Q37554391 | Heart failure: epidemiology and prevention in India |
| Q36080332 | Heart healthy equals prostate healthy and statins, aspirin, and/or metformin (S.A.M.) are the ideal recommendations for prostate cancer prevention |
| Q46480312 | Heterogeneity and weak coupling may explain the synchronization characteristics of cells in the arterial wall |
| Q50086673 | Heterogeneity of Clinical Trials for Antihypertensive Drugs in Japan: Exploratory Analysis of Confirmatory Phase III Trials Used for Marketing Approval |
| Q34572240 | High prevalence and low awareness of hypertension in a market population in enugu, Nigeria |
| Q44431429 | Highly interactive multi-session programs impact physician behavior on hypertension management: outcomes of a new CME model |
| Q61456672 | Home blood pressure measurement and its relationship with blood pressure control in a large selected hypertensive population |
| Q47108474 | How Shall We Manage Isolated Systolic Hypertension in Older Adults? Case Example and Suggestions |
| Q35206393 | How to ADVANCE prevention of cardiovascular complications in type 2 diabetes |
| Q36829011 | How to treat hypertension in patients with peripheral artery disease |
| Q35108210 | How well are we managing and monitoring high blood pressure? |
| Q34726547 | Human aldosterone synthase gene polymorphism promotes miRNA binding and regulates gene expression |
| Q37234916 | Human angiotensinogen +11525 C/A polymorphism modulates its gene expression through microRNA binding |
| Q37164180 | Hypertension Treatment ACCORDing to SPRINT |
| Q47988966 | Hypertension and Exercise Training: Evidence from Clinical Studies. |
| Q26745496 | Hypertension and Related Cardiovascular Disease Burden in China |
| Q38650598 | Hypertension and blood pressure variability management practices among physicians in Singapore. |
| Q36290868 | Hypertension and peripheral arterial disease |
| Q38702269 | Hypertension and stroke: an appraisal of the evidence and implications for clinical management |
| Q35738465 | Hypertension and the vascular patient |
| Q34894104 | Hypertension awareness, treatment and control in Africa: a systematic review |
| Q37050159 | Hypertension control in the elderly |
| Q50698339 | Hypertension guidelines in elderly patients: is anybody listening? |
| Q84661494 | Hypertension in the ED: a multifaceted intervention to change provider practice |
| Q34194758 | Hypertension management 2011: optimal combination therapy |
| Q33932224 | Hypertension management: an update |
| Q36652960 | Hypertension pharmacogenomics: in search of personalized treatment approaches |
| Q77587971 | Hypertension therapeutic research: a plea for change in the new millennium |
| Q24242787 | Hypolipidemic and antihypertensive drugs for prevention of cardiovascular complications in patients with rheumatoid arthritis |
| Q48320737 | Hypothetical interventions to prevent stroke: an application of the parametric g-formula to a healthy middle-aged population |
| Q34634131 | Imidapril: a review of its use in essential hypertension, Type 1 diabetic nephropathy and chronic heart failure |
| Q57490169 | Impact of Home Blood Pressure Telemonitoring and Blood Pressure Control: A Meta-Analysis of Randomized Controlled Studies |
| Q36942911 | Impact of Hospitalization on Antihypertensive Pharmacotherapy among Older Persons |
| Q43844335 | Impact of circadian amplitude and chronotherapy: relevance to prevention and treatment of stroke |
| Q36095388 | Impact of insurance and supply of health professionals on coverage of treatment for hypertension in Mexico: population based study |
| Q37239716 | Implementation of guidelines for the management of arterial hypertension. The impulsion study |
| Q37455654 | Implications of recent clinical trials on pay-for-performance |
| Q36276326 | Importance of controlling blood pressure |
| Q47869510 | Improving the management of hypertension in Kazakhstan: implications for improving clinical practice, patient behaviours and health outcomes |
| Q38118164 | Increasing physical activity for the treatment of hypertension: a systematic review and meta-analysis. |
| Q35886033 | Incremental Blood Pressure-Lowering Effect of Titrating Amlodipine for the Treatment of Hypertension in Patients Including Those Aged ≥55 Years |
| Q95788603 | Inferiority of calcium channel blockers to cheaper drugs. News item was inaccurate on at least two counts |
| Q36025929 | Inflammation, blood pressure, and stroke: an opportunity to target primary prevention? |
| Q36300131 | Influence of the DASH diet and other low-fat, high-carbohydrate diets on blood pressure |
| Q24236536 | Interventions used to improve control of blood pressure in patients with hypertension |
| Q24246318 | Interventions used to improve control of blood pressure in patients with hypertension |
| Q26830308 | Investing in high blood pressure research: a national institutes of health perspective |
| Q37350166 | Is a statin as part of a polypill the answer? |
| Q35896630 | Is choice of antihypertensive agent important in improving cardiovascular outcomes in high-risk hypertensive patients? |
| Q33436451 | Is primary care a neglected piece of the jigsaw in ensuring optimal stroke care? Results of a national study |
| Q57812836 | Ischaemic Stroke and Transient Ischaemic Attack |
| Q55332222 | Knowledge and practices related to stroke prevention among hypertensive and diabetic patients attending Specialist Hospital, Sokoto, Nigeria. |
| Q44431065 | LIFE and ARBITER |
| Q35636620 | LIFE and SCOPE: what guidance do they offer alongside ALLHAT and ANBP2? |
| Q90725902 | Legacy effect in medicine-the expanding horizon! |
| Q24672576 | Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study |
| Q37772422 | Lessons from coronary intravascular ultrasound on the importance of raising high-density lipoprotein cholesterol. |
| Q34317675 | Lessons learned from prematurely terminated clinical trials |
| Q34644804 | Level of blood pressure control among hypertensive patients on follow-up in a regional referral hospital in Central Kenya |
| Q35147022 | Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial |
| Q44693695 | Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial |
| Q33378978 | Literacy and blood pressure--do healthcare systems influence this relationship? A cross-sectional study |
| Q51017958 | Long-Term Anti-Hypertensive Therapy and Stroke Prevention: A Meta-Analysis. |
| Q37145695 | Long-acting nifedipine in the management of the hypertensive patient |
| Q93472100 | Long-term Outcomes of the Effects of Home Blood Pressure Telemonitoring and Pharmacist Management on Blood Pressure Among Adults With Uncontrolled Hypertension: Follow-up of a Cluster Randomized Clinical Trial |
| Q36360341 | Losartan: a review of its use in stroke risk reduction in patients with hypertension and left ventricular hypertrophy |
| Q28214393 | MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial |
| Q33966645 | MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial |
| Q92276483 | Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker-Induced Lower-Extremity Edema With Loop Diuretics |
| Q37785169 | Management of Arterial Blood Pressure in Acute Ischemic and Hemorrhagic Stroke |
| Q87155962 | Management of aortic dissection: medical therapy and intervention. Is there a growing role for endovascular techniques? |
| Q44557173 | Management of asymptomatic carotid artery stenosis. |
| Q38130553 | Management of blood pressure in acute stroke. |
| Q33730536 | Management of cardiovascular complications in systemic lupus erythematosus |
| Q36412642 | Management of extracranial carotid artery disease |
| Q37762263 | Management of high blood pressure in type 2 diabetes: perindopril/indapamide fixed-dose combination and the ADVANCE trial [corrected]. |
| Q36357057 | Management of hypertension and diabetes: treatment goals, drug choices, current practice, and strategies for improving care. |
| Q36102117 | Management of hypertension in solid-organ transplantation |
| Q38181978 | Management of symptomatic carotid disease in 2014. |
| Q35918973 | Managing comorbidities in patients at the end of life |
| Q34824900 | Managing the hypertensive patient with ischemic heart disease |
| Q55278767 | Matão Controlling Hypertension (MatCH) project: Rationale and design. |
| Q39728294 | Measuring the impact of a continuing medical education program on patient blood pressure |
| Q37886792 | Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease |
| Q35682060 | Medical management of chronic ischemic heart disease. Selecting specific drug therapies, modifying risk factors |
| Q36993060 | Medication Adherence and Blood Pressure Control Among Hypertensive Patients With Coexisting Long-Term Conditions in Primary Care Settings: A Cross-Sectional Analysis |
| Q46722300 | Medication adherence and blood pressure control amongst adults with primary hypertension attending a tertiary hospital primary care clinic in Eastern Nigeria. |
| Q34365037 | Meta-analyses of antihypertensive therapy: Are some of them misleading? |
| Q36577861 | Metabolic monitoring for patients treated with antipsychotic medications |
| Q35984038 | Metabolic properties of vasodilating beta blockers: management considerations for hypertensive diabetic patients and patients with the metabolic syndrome |
| Q37024082 | Metabolic side effects and cardiovascular events of diuretics: should a diuretic remain the first choice therapy in hypertension treatment? The case of yes. |
| Q33239013 | Methods underpinning national clinical guidelines for hypertension: describing the evidence shortfall |
| Q37334663 | Metoprolol succinate combination in the treatment of hypertension |
| Q35197102 | Microalbuminuria and diabetic cardiovascular disease |
| Q35087590 | Microalbuminuria in diabetes: focus on cardiovascular and renal risk reduction |
| Q47112964 | Mortality in persons with undetected and diagnosed hypertension, type 2 diabetes, and hypothyroidism, compared with persons without corresponding disease - a prospective cohort study; The HUNT Study, Norway |
| Q28219606 | Multivariate risk assessment and risk score cards in hypertension |
| Q33609742 | Myocardial infarction and stroke associated with diuretic based two drug antihypertensive regimens: population based case-control study. |
| Q37229207 | Nebivolol (bystolic), a novel Beta blocker for hypertension |
| Q44010676 | New strategies for prevention of ischemic stroke: the LIFE study |
| Q34580796 | Nifedipine Gastrointestinal Therapeutic System (GITS) in the treatment of coronary heart disease and hypertension |
| Q37620461 | Novel approaches for treating hypertension |
| Q34079801 | Nurse led interventions to improve control of blood pressure in people with hypertension: systematic review and meta-analysis |
| Q39497957 | Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study |
| Q34772915 | Olmesartan medoxomil for the treatment of hypertension in children and adolescents |
| Q33395038 | Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials |
| Q36568468 | Optimizing hypertension management in clinical practice |
| Q28078922 | PURLs: "Go low" or say "No" to aggressive systolic BP goals? |
| Q34142036 | Pathophysiologic therapeutic targets in hypertension: a cardiological point of view. |
| Q39731543 | Patterns and predictors of prehypertension among "healthy'' urban adults in India |
| Q91871063 | Perceptions and Practices towards Medication Non-Adherence among Hypertensive Patients: An Observational Study |
| Q42864618 | Perindopril for improving cardiovascular events |
| Q37041380 | Perindopril: do randomised, controlled trials support an ACE inhibitor class effect? A meta-analysis of clinical trials. |
| Q34450527 | Perindopril: the evidence of its therapeutic impact in hypertension. |
| Q34307609 | Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study |
| Q98163696 | Pharmacokinetic interactions of esaxerenone with amlodipine and digoxin in healthy Japanese subjects |
| Q28282619 | Pharmacological effects of AVE 0991, a nonpeptide angiotensin-(1-7) receptor agonist |
| Q34520806 | Pharmacotherapy in congestive heart failure. Prematurely terminated clinical trials and their application to cardiovascular medicine |
| Q46806767 | Predictors of compliance with antihypertensive therapy in a high-risk medicaid population |
| Q37392492 | Predictors of hypertension awareness, treatment, and control among Mexican American women and men |
| Q36983765 | Prehypertension during young adulthood and coronary calcium later in life |
| Q79971902 | Prevalence and determinants of undertreatment of hypertension in the Netherlands |
| Q33889572 | Prevalence and predictors of resistant hypertension in a primary care setting: a cross-sectional study |
| Q36729200 | Prevalence and treatment of isolated and concurrent hypertension and hypercholesterolaemia in the United Kingdom |
| Q43885926 | Prevalence of chronic renal failure in primary care |
| Q36704268 | Prevalence of comorbidities and their influence on blood pressure goal attainment in geriatric patients |
| Q35782644 | Prevalence of hypertension and its treatment among adults presenting to primary health clinics in rural Zambia: Analysis of an observational database |
| Q37728148 | Prevalence, Awareness, Treatment, and Control of Hypertension among Kazakhs with high Salt Intake in Xinjiang, China: A Community-based Cross-sectional Study |
| Q46130027 | Prevalence, awareness, treatment and control of hypertension among adults in rural north-western China: a cross-sectional population survey |
| Q35120857 | Prevention and management of chronic heart failure in patients at risk |
| Q37171471 | Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis |
| Q35818904 | Prevention and treatment of stroke in patients with hypertension |
| Q35770938 | Prevention of cardiovascular diseases: focus on modifiable cardiovascular risk |
| Q37104525 | Prevention of cardiovascular events by treating hypertension in older adults: an evidence-based approach |
| Q35933720 | Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system |
| Q59132504 | Preventive Effect of Hydroalcoholic Extract of on Cardiovascular Parameters in Acute Hypertensive Rats Induced by Angiotensin II |
| Q37984281 | Preventive aspects in peripheral artery disease |
| Q36905137 | Primary and secondary prevention of stroke by antihypertensive treatment in clinical trials |
| Q28217877 | Primary prevention of cardiovascular disease: cost-effectiveness comparison |
| Q30503671 | Primary prevention of cardiovascular diseases: a cost study in family practices |
| Q22306369 | Primary prevention of ischemic stroke |
| Q28213134 | Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of stroke |
| Q43923238 | Progress in reducing the burden of stroke. |
| Q34978647 | Projected impact of polypill use among US adults: Medication use, cardiovascular risk reduction, and side effects |
| Q34317665 | Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes |
| Q35043178 | Pulse Pressure Is Useful for Determining the Choice of Antihypertensive Drugs in Postmenopausal Women |
| Q82914480 | Quality measurement as a prerequisite for improving hypertension control in an academic medical center |
| Q39865589 | Quantifying links between stroke and risk factors: a study on individual health risk appraisal of stroke in a community of Chongqing |
| Q28180976 | Queen Mary Utilization of Antihypertensive Drugs Study: use of antihypertensive drug classes in the hypertension clinic 1996-2004 |
| Q40073611 | RAS Inhibitor Is Not Associated With Cardiovascular Benefits in Patients Undergoing Hemodialysis in Japan. |
| Q39731657 | Ramipril use in Canada: HOPE or HYPE? |
| Q28190600 | Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack |
| Q34199986 | Recent clinical trial highlights in hypertension |
| Q37167414 | Recommendations on screening for high blood pressure in Canadian adults |
| Q90789486 | Redefining Blood Pressure Assessment - The Role of the Ambulatory Blood Pressure Monitoring Study for Drug Safety |
| Q37635112 | Reduction of blood pressure in patients with treatment-resistant hypertension |
| Q83304439 | Reforming health care or reforming health? |
| Q35058619 | Regression of left ventricular hypertrophy: hoping for a longer life |
| Q59049737 | Relationship between Body Mass Index, Blood Pressure, and Visual Acuity in Residents of Esan West Local Government Area of Edo State, Nigeria |
| Q37635465 | Relationship between outdoor temperature and cardiovascular disease risk factors in older people |
| Q37382259 | Relationships between blood pressure and health and fitness-related variables in obese women |
| Q33580740 | Relaxation of rat aorta by farrerol correlates with potency to reduce intracellular calcium of VSMCs |
| Q33641528 | Renal denervation using an irrigated catheter in patients with resistant hypertension: a promising strategy? |
| Q38106489 | Renal sympathetic denervation: hypertension therapy and beyond |
| Q37051483 | Renin inhibitors: optimal strategy for renal protection |
| Q34124779 | Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status |
| Q37802083 | Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends |
| Q36557597 | Resistant hypertension: diagnosis and management |
| Q33895122 | Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study |
| Q80506852 | Retrospective longitudinal cohort study comparing the effects of angiotensin-converting enzyme inhibitors and long-acting calcium channel blockers on total and cardiovascular mortality in patients with hypertension |
| Q37153566 | Risk factor management to prevent first stroke |
| Q36979914 | Role of angiotensin receptor blockers in the prevention and management of ischaemic stroke. |
| Q38069195 | Role of dihydropyridinic calcium channel blockers in the management of hypertension. |
| Q89399239 | Role of the Pharmacoeconomic Aspects in the Clinical Management of Hypertension |
| Q35210547 | Safety and tolerability of fixed antihypertensive combinations in blood pressure control: focus on olmesartan medoxomil and amlodipine combination |
| Q42624044 | Safety of telmisartan in patients with arterial hypertension : an open-label observational study |
| Q34974619 | Secondary prevention of stroke: old and new evidence |
| Q22306384 | Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure |
| Q64055878 | Sex difference in the incidence of stroke and its corresponding influence factors: results from a follow-up 8.4 years of rural China hypertensive prospective cohort study |
| Q46239465 | Sex differences in blood pressure response to antihypertensive therapy in Chinese patients with hypertension |
| Q34961436 | Short Form (SF-36) Health Survey measures are associated with decreased adherence among urban African Americans with severe, poorly controlled hypertension |
| Q34144860 | Socioeconomic inequality in salt intake in Britain 10 years after a national salt reduction programme. |
| Q43266393 | Socioeconomic relevance of selected treatment strategies in patients with chronic heart failure |
| Q26738584 | Stabilization of high-risk plaques |
| Q28279570 | Stroke |
| Q46504493 | Stroke and coronary heart disease in treated hypertension -- a prospective cohort study over three decades |
| Q28200179 | Stroke prevention in diabetes and obesity |
| Q37136973 | Stroke risk screening of adults with hypertension: prospective cross-sectional study in primary care |
| Q37063557 | Submaximal fitness and mortality risk reduction in coronary heart disease: a retrospective cohort study of community-based exercise rehabilitation |
| Q36183802 | Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice |
| Q36416112 | Systemic inflammation, blood pressure, and stroke outcome. |
| Q38814884 | Systolic Blood Pressure and Risk of Type 2 Diabetes: A Mendelian Randomization Study |
| Q36069269 | Systolic blood pressure levels among adults with hypertension and incident cardiovascular events: the atherosclerosis risk in communities study |
| Q35660077 | TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats |
| Q36302833 | Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers |
| Q37253018 | Telmisartan/Hydrochlorothiazide: a review of its use as fixed-dose combinations in essential hypertension |
| Q42975891 | Testing a TheoRY-inspired MEssage ('TRY-ME'): a sub-trial within the Ontario Printed Educational Message (OPEM) trial |
| Q34607311 | The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy |
| Q44295771 | The ALLHAT report: a case of information and misinformation |
| Q73337475 | The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic |
| Q37156484 | The DASH Diet and Insulin Sensitivity |
| Q35227768 | The Dietary Approaches to Stop Hypertension (DASH) eating pattern in special populations. |
| Q34317630 | The INSIGHT and NORDIL trials: Are calcium antagonists equivalent to established drug therapies for cardiovascular protection? |
| Q36412693 | The Ontario printed educational message (OPEM) trial to narrow the evidence-practice gap with respect to prescribing practices of general and family physicians: a cluster randomized controlled trial, targeting the care of individuals with diabetes a |
| Q40243519 | The PROGRESS trial three years later: time for a balanced report of effectiveness |
| Q35086790 | The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): clinical implications for older patients with cerebrovascular disease |
| Q34377220 | The Polymeal: a more natural, safer, and probably tastier (than the Polypill) strategy to reduce cardiovascular disease by more than 75%. |
| Q91844822 | The Precision HYpertenSIon Care (PHYSIC) study: a double-blind, randomized, repeated cross-over study |
| Q42407877 | The Search for Strategies to Control Hypertension |
| Q35587336 | The Use of Calcium Antagonists in the Therapy of Hypertension in the Elderly |
| Q64910749 | The Value of Elderly Disease Prevention. |
| Q34365083 | The calcium channel blocker controversy in patients with diabetic nephropathy: Is there an issue? |
| Q34145516 | The design and rationale of a multicenter clinical trial comparing two strategies for control of systolic blood pressure: the Systolic Blood Pressure Intervention Trial (SPRINT) |
| Q82521293 | The doctor needs to see you now: accelerating the care of patients with uncontrolled hypertension |
| Q34209022 | The economic impact of hypertension |
| Q38751502 | The effect of antihypertensive treatment on the incidence of stroke and cognitive decline in the elderly: a meta-analysis |
| Q33557881 | The features of reserpine-induced gastric mucosal lesions |
| Q36569409 | The first Iranian recommendations on prevention, evaluation and management of high blood pressure |
| Q44564248 | The first hypertension trial comparing the effects of two fixed-dose combination therapy regimens on cardiovascular events: Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH). |
| Q36801003 | The healthcare burden of hypertension in Asia |
| Q37050147 | The importance of prompt blood pressure control |
| Q36554941 | The latest generation of beta-blockers: new pharmacologic properties |
| Q46846774 | The management of systemic hypertension in optometric practice |
| Q36792862 | The patient with cardiovascular disease: treatment strategies for preventing major events |
| Q24801524 | The potential savings of using thiazides as the first choice antihypertensive drug: cost-minimisation analysis |
| Q34482780 | The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy |
| Q37995862 | The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications |
| Q37566079 | The role of RAS modification for primary and secondary stroke prevention |
| Q34401862 | The role of angiotensin-converting enzyme inhibitors in the treatment of hypertension |
| Q39731644 | The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario. |
| Q46636892 | The treat-to-target paradigm: a cross-sectional survey of current therapies and achieved metabolic control in 800 type 2 diabetic patients |
| Q34633321 | The use of calcium antagonists in the treatment of hypertensive persons with kidney disease |
| Q41657350 | Therapy with the Combination of Amlodipine and Irbesartan Has Persistent Preventative Effects on Stroke Onset Associated with BDNF Preservation on Cerebral Vessels in Hypertensive Rats |
| Q45650698 | Time to achieve first blood pressure control after diagnosis among hypertensive patients at primary health care clinics: a preliminary study |
| Q37657817 | Traditional Chinese medicine suppresses left ventricular hypertrophy by targeting extracellular signal-regulated kinases signaling pathway in spontaneously hypertensive rats |
| Q73091312 | Translating worldwide calcium-channel blocker experience into clinical practice |
| Q35629529 | Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? |
| Q37151940 | Treating to protect: current cardiovascular treatment approaches and remaining needs. |
| Q57809367 | Treatment adherence and blood pressure outcome among hypertensive out-patients in two tertiary hospitals in Sokoto, Northwestern Nigeria |
| Q24558616 | Treatment of Hypertension in the UK: Simple as ABCD? |
| Q36933054 | Treatment of hypertension among African Americans: the Jackson Heart Study |
| Q35215068 | Treatment of hypertension in older patients: an updated look at the role of calcium antagonists |
| Q34047349 | Treatment of hypertension with renin-angiotensin system inhibitors and renal dysfunction: a systematic review and meta-analysis. |
| Q35648075 | Treatment of risk factors to prevent stroke |
| Q34721512 | Treatment options for hypertension in high-risk patients |
| Q44981485 | Treatment principles for the metabolic syndrome |
| Q48159467 | Trends in risk factors, patterns and causes in hospitalized strokes over 25 years: The Lausanne Stroke Registry. |
| Q35143212 | Trials on blood pressure-lowering and secondary stroke prevention. |
| Q36426826 | Triamterene Enhances the Blood Pressure Lowering Effect of Hydrochlorothiazide in Patients with Hypertension |
| Q34051241 | Unmasking masked hypertension: prevalence, clinical implications, diagnosis, correlates and future directions. |
| Q38805043 | Update in the management of type B aortic dissection. |
| Q79219460 | Update on the management of hypertension to prevent stroke |
| Q34622317 | Update on the use of calcium antagonists on hypertension |
| Q34614447 | Use of Angiotensin receptor blockers in cardiovascular protection: current evidence and future directions |
| Q31115388 | Use of Pharmacy Sales Data to Assess Changes in Prescription- and Payment-Related Factors that Promote Adherence to Medications Commonly Used to Treat Hypertension, 2009 and 2014. |
| Q90569023 | Use of Prescription Medications That Potentially Interfere With Blood Pressure Control in New-Onset Hypertension and Treatment-Resistant Hypertension |
| Q51169128 | Use of annual ABPM, and repeated carotid scan and echocardiography to monitor cardiovascular health over nine yr in pediatric and young adult renal transplant recipients. |
| Q24658205 | Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies |
| Q35839491 | Use of calcium channel antagonists for the treatment of hypertension in the elderly |
| Q45012662 | Use of calcium channel blockers as antihypertensives in relation to mortality and cancer incidence: a population-based observational study |
| Q36050471 | Use of nifedipine in the treatment of hypertension |
| Q46366785 | Validation of a decision model for preventive pharmacological strategies in postmenopausal women |
| Q37581620 | Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy |
| Q35107962 | Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials |
| Q37688028 | Variability in the prescription of cardiovascular medications in older patients: correlates and potential explanations. |
| Q24236765 | Walking for hypertension |
| Q33805317 | What are the elements of good treatment for hypertension? |
| Q37925640 | What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease? |
| Q30333019 | Why not prescribe the best drugs for hypertension now? |
| Q51642485 | Women with prehypertension in primary care - Risk profile on the basis of selected cardiovascular risk factors. |
| Q47197086 | Work-site hypertension prevalence and control in three Central European Countries |
| Q34397337 | Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients |
| Q77165888 | [Arterial hypertension and atherosclerosis: beyond hemodynamic stress] |
| Q80587364 | [Arterial hypertension and dementia] |
| Q81657334 | [Blood pressure and the brain] |
| Q78889549 | [COPD: from unjustified nihilism to reasonable optimism] |
| Q97415132 | [Diagnostic and Therapeutic Management of Carotid Artery Disease] |
| Q73800179 | [Differentiation and evaluation of calcium antagonists in therapy of arterial hypertension] |
| Q73727707 | [Diuretics and cardiovascular outcome in hypertensive patients: an update] |
| Q81691991 | [European Stroke Organisation 2008 guidelines for managing acute cerebral infarction or transient ischemic attack : part 2] |
| Q81657541 | [New guidelines for treatment of hypertension] |
| Q79928810 | [Recommendations of the European Stroke Initiative (EUSI) for treatment of ischemic stroke--update 2003. Part 2: prevention and rehabilitation] |
| Q80103475 | [Spontaneous intracerebral hemorrhages] |
| Q45118824 | [Use of antihypertensive agents in Cantabria, Spain [1995-2002]: discrepancy with the published evidence]. |
| Q79850934 | [Use of antihypertensive drugs in Spain (1995-2001)] |
| Q45910269 | Recommandations pour le dépistage de l’hypertension chez les adultes canadiens. |
| Q24806038 | A novel approach to treatment of hypertension in diabetic patients - a multicenter, double-blind, randomized study comparing the efficacy of combination therapy of Eprosartan versus Ramipril with low-dose Hydrochlorothiazide and Moxonidine on blood |